Thursday, October 21, 2010 7:21 PM
|
Ken Torbert
The provincial government has finally stepped up - sort of - when it comes to pursuing a potentially effective treatment for those who suffer from Multiple Sclerosis. Manitoba Health Minister Theresa Oswald announced last Friday that the province is setting aside $500,000 for possible future trials of the "MS Liberation
Treatment". Oswald said the funds are for clinical tests of the controversial treatment
and will be made available if and when the treatment is proven to be
what the province describes as "safe and appropriate" for MS sufferers.Developed By Dr. Paolo Zamboni The treatment was developed by Italian doctor Paolo Zamboni, a former vascular surgeon and professor at the University of Ferrara in northern
Italy. He created the treatments after he started asking questions about
MS 10 years ago, when his wife Elena was diagnosed with the disease. Zamboni found scientists who studied the brains of MS patients and noticed higher levels of iron in their brain not accounted for by age. The
deposits had a unique pattern, often forming in the core of the brain,
clustered around veins that generally drain blood from the head. And the Italian physician said no one had ever fully explained this condition other than stating the excess iron was a toxic by-product of
MS. Zamboni believes many MS patients have a narrow-vein condition known as chronic cerebrospinal venous insufficiency (CCSVI). The condition - he said - is relieved by unblocking the veins with a balloon
angioplasty procedure that can alleviate MS symptoms. Saskatchewan has already they will pay for "liberation" clinical trials if scientific evidence shows it could significantly help patients. And
other provinces like Nova Scotia said it would follow suit. Quebec is
also considering funding national trials along with the government of
Newfoundland and Labrador. Want More Evidence However, the Canadian Institutes of Health Research stated late this past summer there isn't enough evidence to support such pan-Canadian clinical
trials.
http://www.carmanvalleyleader.com/ArticleDisplay.aspx?e=2808371
|